David E. Moller

Sciences Po Lyon — France

Biochemistry, Genetics and Molecular Biology · Life Sciences

77h-index32.0kcitations214works0.02yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Metabolism, Diabetes, and Cancer(75), Peroxisome Proliferator-Activated Receptors(71), Adipose Tissue and Metabolism(61), Pancreatic function and diabetes(38), Adipokines, Inflammation, and Metabolic Diseases(21)

Publications214 total

A novel direct adenosine monophosphate kinase activator ameliorates disease progression in preclinical models of Autosomal Dominant Polycystic Kidney Disease
Kidney International·2023· 20 citedOpen Access
Evaluation of PXL065 – deuterium-stabilized (R)-pioglitazone in patients with NASH: A phase II randomized placebo-controlled trial (DESTINY-1)
Journal of Hepatology·2023· 68 citedOpen Access
Beneficial Effects of the Direct AMP-Kinase Activator PXL770 in In Vitro and In Vivo Models of X-Linked Adrenoleukodystrophy
Journal of Pharmacology and Experimental Therapeutics·2022· 7 citedOpen Access
Therapeutic potential of deuterium‐stabilized (<i>R</i>)‐pioglitazone—<scp>PXL065</scp>—for X‐linked adrenoleukodystrophy
Journal of Inherited Metabolic Disease·2022· 14 citedOpen Access
MO019: Preclinical Efficacy of Direct AMPK Activation with a Novel Small Molecule–PXL770–For the Treatment of Autosomal Dominant Polycystic Kidney Disease
Nephrology Dialysis Transplantation·2022
Reduced lactic acidosis risk with Imeglimin: Comparison with Metformin
Physiological Reports·2022· 33 citedOpen Access
Pharmacodynamic effects of direct AMP kinase activation in humans with insulin resistance and non-alcoholic fatty liver disease: A phase 1b study
Cell Reports Medicine·2021· 42 citedOpen Access
Validation of direct AMP kinase (AMPK) activation for treatment of X-linked Adrenoleukodystrophy
Journal of the Neurological Sciences·2021
Efficacy and safety of PXL770, a direct AMP kinase activator, for the treatment of non-alcoholic fatty liver disease (STAMP-NAFLD): a randomised, double-blind, placebo-controlled, phase 2a study
˜The œLancet. Gastroenterology & hepatology·2021· 62 cited
Direct AMPK Activation Corrects NASH in Rodents Through Metabolic Effects and Direct Action on Inflammation and Fibrogenesis
Hepatology Communications·2021· 72 citedOpen Access
Imeglimin amplifies glucose-stimulated insulin release from diabetic islets via a distinct mechanism of action
PLoS ONE·2021· 83 citedOpen Access
Mechanism of action of Imeglimin: A novel therapeutic agent for type 2 diabetes
Diabetes Obesity and Metabolism·2020· 174 citedOpen Access
Author response for "Mechanism Of Action Of Imeglimin – A Novel Therapeutic Agent For Type 2 Diabetes"
2020· 1 cited
Imeglimin preserves islet β‐cell mass in Type 2 diabetic ZDF rats
Endocrinology Diabetes & Metabolism·2020· 54 citedOpen Access
Imeglimin Amplifies Glucose-Stimulated Insulin Release from Diabetic Islets via a Distinct Mechanism of Action
2020· 7 citedOpen Access
SEMISYNTHESIS OF NOVEL MACROLIDE-BASED ANTIBIOTICS
Proceedings of European Symposium on Organic Chemistry 2019·2019
Erfolgreiche Prolongation einer Geminigravidität um 18 SSW durch Muttermundsverschluss (TMV) nach Spontanabort des ersten Geminus
Zeitschrift für Geburtshilfe und Neonatologie·2017
Erratum. Evaluation of Efficacy and Safety of the Glucagon Receptor Antagonist LY2409021 in Patients With Type 2 Diabetes: 12- and 24-Week Phase 2 Studies. Diabetes Care 2016;39:1241–1249
Diabetes Care·2017· 5 citedOpen Access
Response to Comment on Kazda et al. Evaluation of Efficacy and Safety of the Glucagon Receptor Antagonist LY2409021 in Patients With Type 2 Diabetes: 12- and 24-Week Phase 2 Studies. Diabetes Care 2016;39:1241–1249
Diabetes Care·2016· 10 cited
Ribosomal subunit kinasE factor-stimulated transcri
2016
page 1 of 11Next →

Frequent Co-authors

Joel P. Berger(13), Gaochao Zhou(8), Thomas W. Doebber(7), Alex Elbrecht(7), John Ventre(6), Jeffrey S. Flier(6), Bei B. Zhang(6), Margaret Wu(5), Roy G. Smith(5), Laurie J. Goodyear(4), Alexei Kharitonenkov(4), Michael Tanen(4), Deborah Szalkowski(4), Karen L. MacNaul(4), Yuli Chen(3), Judy Fenyk‐Melody(3), Nicolas Musi(3), Michael F. Hirshman(3), Zhihua Li(3), Mark D. Leibowitz(3)